8-K: Elicio Therapeutics Presents Promising Data for ELI-002 Cancer Vaccine at SITC 2024

Elicio Therapeutics announced updated data from its ELI-002 Phase 1 trial showing a correlation between T cell response and disease-free survival in patients with mKRAS-driven solid tumors.

Summary

• Elicio Therapeutics presented updated data from the Phase 1 AMPLIFY-7P trial of its ELI-002 cancer vaccine at the Society for Immunotherapy of Cancer 2024 Annual Meeting.
• The study evaluated ELI-002 in patients with mKRAS-driven solid tumors who are at risk of disease recurrence.
• The data showed that ELI-002 induced T cell responses against KRAS mutations and patient-specific neoantigens.
• A correlation was observed between the magnitude of T cell response and the duration of disease-free survival (DFS).
• The median T cell response in the 4.9 mg dose group was 12-fold higher than the 1.4 mg dose group.
• The highest three quartiles of T cell responders have not yet reached median DFS, while the lowest quartile achieved a median DFS of 3.1 months.
• Antigen spreading was detected in all patients treated with the recommended Phase 2 dose, with T cell responses observed against 67.5% of tested neoantigens.
• ELI-002 was found to be safe and well-tolerated, with no dose-limiting toxicities or cytokine release syndrome observed.
• The Phase 2 interim event-driven DFS analysis is expected in the first half of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data with a clear correlation between T cell response and disease-free survival, along with a favorable safety profile. The potential for broader tumor immunosurveillance is also encouraging. However, the company's financial condition and the inherent risks of clinical trials temper the overall sentiment.

Positives

• The ELI-002 vaccine showed a robust expansion of T cells targeting mutant KRAS antigens.
• There is a clear relationship between T cell response and disease-free survival.
• The vaccine induced T cell reactivity against personalized neoantigens, which could improve the breadth and durability of tumor immunosurveillance.
• The safety and tolerability profile of ELI-002 remains favorable.
• The study showed that T cell responses against mKRAS antigens were durable, extending up to 1.5 years.

Risks

• The company's financial condition and ability to obtain funding are risks to the development of ELI-002.
• The timing of clinical trials and data availability are subject to change.
• The company's ability to commercialize its product candidates is not guaranteed.
• The company's estimates regarding future revenue, expenses, and capital requirements may not be accurate.

Future Outlook

The company expects to provide an additional clinical data update from the AMPLIFY-201 trial in December 2024 and anticipates an interim event-driven DFS analysis from the AMPLIFY-7P trial in the first half of 2025.

Management Comments

• Christopher Haqq, M.D., Ph.D., Elicio's Executive Vice President, Head of Research and Development and Chief Medical Officer, stated that they are encouraged to see a robust expansion of T cells targeting mutant KRAS antigens and a clear relationship between T cell response and DFS.
• He also noted that they are encouraged by the observed induced T cell reactivity against personalized neoantigens, which could improve the breadth and durability of tumor immunosurveillance.

Industry Context

This announcement is significant in the context of the broader cancer immunotherapy field, particularly in the development of personalized cancer vaccines and treatments targeting KRAS mutations, which are prevalent in many solid tumors. The results suggest a potential for Elicio's AMP technology to enhance the effectiveness of cancer vaccines.

Comparison to Industry Standards

• The results of the ELI-002 trial are being compared to other cancer vaccine trials, particularly those targeting KRAS mutations.
• The observed correlation between T cell response and DFS is a key metric that is being closely watched in the field.
• The antigen spreading observed in the study is a promising sign that the vaccine may be able to induce a broader immune response.
• The safety and tolerability profile of ELI-002 is also being compared to other cancer immunotherapies.

Stakeholder Impact

• Shareholders may react positively to the promising clinical data.
• Patients with mKRAS-driven solid tumors may benefit from the development of ELI-002.
• Employees of Elicio Therapeutics may be motivated by the positive results.
• The company's suppliers and partners may see increased opportunities.

Next Steps

• The company expects to complete enrollment for the AMPLIFY-7P Phase 2 randomized clinical trial in the fourth quarter of 2024.
• An additional clinical data update from the AMPLIFY-201 trial is expected in December 2024.
• The Phase 2 interim event-driven DFS analysis from the AMPLIFY-7P trial is expected in the first half of 2025.

Key Dates

Keywords

ELI-002, cancer vaccine, immunotherapy, KRAS mutations, T cell response, disease-free survival, neoantigens, AMPLIFY-7P, pancreatic cancer, solid tumors